iGMDRD112
| Standard Name | CHEMBL | Pubchem CID | KEGG Drug ID | DRUGBANK ID | Drug Status | Drug targets (TTD) | Drug Type |
|---|---|---|---|---|---|---|---|
| Methotrexate | CHEMBL3244648 CHEMBL34259 CHEMBL1376974 | 126941 | D02115 | DB00563 | Alone | DNC000933 | Small Molecule |
Drug Class:
Abortifacient AgentsAbortifacient Agents, NonsteroidalAminopterinAntimetabolitesAntimetabolites, AntineoplasticAntineoplastic AgentsAntineoplastic and Immunomodulating AgentsAntirheumatic AgentsBCRP/ABCG2 SubstratesBiological FactorsCardiotoxic antineoplastic agentsDermatologicalsEnzyme InhibitorsFolate Analog Metabolic InhibitorFolic Acid AnaloguesFolic Acid AntagonistsHeterocyclic CompoundsHeterocyclic Compounds, 2-RingImmunologic FactorsImmunosuppressive AgentsMyelosuppressive AgentsNoxaeNucleic Acid Synthesis InhibitorsOAT3 SubstratesOATP1B1/SLCO1B1 SubstratesP-glycoprotein/ABCB1 SubstratesPigments, BiologicalPteridinesPterinsReproductive Control AgentsToxic ActionsDrug-model tissue-cancer distribution: Bubble Plot
Drug-gene pathway enrichments
Drug-gene GO enrichments
Drug-Gene: Aster Plot
| Gene ID | Gene Name | Model Num. |
|---|---|---|
| 8266 | UBL4A | 1 |
| 9757 | KMT2B | 1 |
| 1387 | CREBBP | 1 |
| 1111 | CHEK1 | 1 |
| 4851 | NOTCH1 | 1 |
| 7158 | TP53BP1 | 1 |
| 238 | ALK | 1 |
| 2064 | ERBB2 | 1 |
| 983 | CDK1 | 1 |
| 6850 | SYK | 1 |
| 10413 | YAP1 | 1 |
| 3932 | LCK | 1 |
| 7157 | TP53 | 1 |
| 3673 | ITGA2 | 1 |
| 3791 | KDR | 1 |
| 4086 | SMAD1 | 1 |
| 2309 | FOXO3 | 1 |
| 4904 | YBX1 | 1 |
| 4089 | SMAD4 | 1 |
| 1956 | EGFR | 1 |
| 3553 | IL1B | 1 |
| 1977 | EIF4E | 1 |
| 2648 | KAT2A | 1 |
| 9223 | MAGI1 | 1 |
| 5111 | PCNA | 1 |
| 100862685 | ERVK-19 | 1 |
| 2065 | ERBB3 | 1 |
| 54790 | TET2 | 1 |
| 142 | PARP1 | 1 |
| 4763 | NF1 | 1 |
Gene in drug-gene network: Network Plot
Models in Methotrexate

